vaccin
extrem
import
public
health
measur
demonstr
prophylact
therapeut
util
mani
infecti
impact
form
past
decad
advanc
materi
engin
allow
develop
studi
new
gener
nanoparticl
hepat
b
human
papillomaviru
hpv
vaccin
exampl
particl
vlp
impact
million
nanoparticl
may
come
sever
shape
form
inorgan
nontox
vlp
protein
nanoparticl
sapn
scaffold
present
antigen
repetit
multimer
manner
robustli
stimul
immun
anim
howev
intrins
product
challeng
imped
broader
translat
nanovaccin
clinic
vlp
vaccin
often
produc
low
yield
mammalian
cell
line
difficult
purifi
requir
complex
reassembl
process
addit
product
hpv
vlp
exampl
requir
three
sequenti
purif
step
strong
cation
exchang
chromatographi
chromatographi
sec
hydroxyapatit
product
nanovaccin
challeng
slight
variat
method
product
result
heterogen
liposom
product
nanovaccin
global
market
could
therefor
requir
special
pipelin
rais
cost
addit
regulatori
approv
drug
use
human
complex
develop
multicompon
technolog
would
allow
de
novo
nanoparticl
assembl
host
materi
inexpens
simpl
stabl
bypass
complex
biochem
process
downstream
purif
may
interest
regard
comput
protein
engin
extrem
power
tool
facilit
design
novel
well
specif
potent
one
exampl
prime
immunogen
engin
activ
precursor
broadli
neutral
scaffold
lumazin
synthas
ls
enzym
aquifex
aeolicu
assembl
mer
nanoparticl
induc
stronger
humor
immun
higher
frequenc
igg
memori
b
term
vaccin
deliveri
dna
vaccin
studi
induct
humor
cellular
addit
deliveri
optim
dna
plasmid
encod
monomer
immunogen
via
adapt
control
electropor
ep
result
enhanc
vivo
express
vivo
product
encod
newer
dna
platform
also
robust
method
elicit
adapt
immun
respons
human
demonstr
immun
potenc
clinic
diseas
zika
ebola
hiv
middl
east
respiratori
syndrom
clinic
efficaci
cervic
simpl
multimer
domain
heptam
domain
employ
improv
dna
vaccin
explor
expand
upon
concept
focus
induct
respons
larg
comput
design
nanoparticl
mer
decor
varieti
antigen
current
clinic
evalu
recombin
protein
examin
prototyp
dna
deliveri
discov
nanoparticl
lumazin
synthas
decor
immunogen
herein
refer
could
assembl
vivo
nanoparticl
induc
stronger
humor
respons
correspond
monomer
mice
guinea
pig
also
uniqu
elicit
immun
unlik
correspond
protein
nanovaccin
comput
design
altern
nanoparticl
scaffold
util
differ
immunogen
evalu
approach
broadli
consist
improv
induct
adapt
immun
respons
observ
across
multipl
construct
shown
confer
signific
benefit
protect
mice
lethal
influenza
challeng
synthet
dnaelectropor
dnaep
technolog
therefor
use
direct
vivo
assembl
comput
design
nanovaccin
elicit
potent
function
immunolog
respons
combin
like
import
rapid
develop
vaccin
immunotherapi
determin
whether
dnaep
could
use
launch
structur
design
sapn
vivo
encod
transgen
vector
optim
dna
cassett
vivo
nanoparticl
express
figur
first
evalu
express
secret
assembl
plasmid
encod
construct
vitro
engin
construct
incorpor
optim
human
found
vitro
intracellular
express
construct
strongli
enhanc
compar
construct
without
leader
sequenc
figur
support
inform
therefor
use
ige
construct
subsequ
experi
addit
reduc
analysi
transfect
supernat
support
could
secret
figur
support
inform
protein
elut
homogen
fraction
sec
figur
support
inform
assembl
protein
observ
approxim
mda
determin
protein
conjug
analysi
multiangl
light
scatter
figur
neg
stain
electron
microscopi
nsem
also
support
correct
assembl
protein
diamet
around
nm
figur
next
examin
vivo
express
monom
nanoparticl
construct
immunofluoresc
stain
mous
muscl
transfect
dnaep
day
dpi
human
broadli
neutral
antibodi
show
construct
express
vivo
figur
reduc
western
analys
muscl
homogen
dpi
green
also
confirm
vivo
express
antigen
even
though
vivo
express
stronger
consist
figur
assembl
state
compar
mous
muscl
homogen
examin
page
mer
defin
migrat
pattern
recombin
protein
standard
observ
mice
figur
band
correspond
monomer
oligomer
band
also
observ
muscl
homogen
significantli
less
intens
mer
band
may
repres
newli
synthes
partial
assembl
transit
cellular
secretori
network
next
use
lectin
mbl
label
experi
assess
vivo
antigen
multimer
nanoparticl
assembl
mbl
protein
form
hexam
preferenti
bind
highli
repeat
glycan
structur
pathogenantigen
recent
studi
tokatilian
et
al
demonstr
highli
multimer
glycan
structur
could
bind
studi
similarli
show
use
elisa
could
bind
protein
murin
mbl
could
bind
protein
protein
figur
e
support
inform
use
assay
multimer
readout
demonstr
could
bind
mbl
figur
g
support
inform
observ
could
strongli
label
endogen
murin
mbl
via
immunohistochemistri
experi
figur
addit
way
assess
vivo
nanoparticl
format
employ
transmiss
electron
techniqu
thin
section
transfect
muscl
stain
igg
cluster
macromolecul
suggest
nanoparticl
decor
multipl
copi
observ
mice
inject
figur
figur
support
inform
mice
cluster
often
valenc
greater
figur
expect
reduct
label
valenc
due
steric
hindranc
bind
individu
subunit
limit
solvent
exposur
nanoparticl
surfac
thin
sampl
section
quantit
measur
order
cluster
differ
field
interest
demonstr
partial
form
order
order
less
nanoparticl
significantli
frequent
mice
treat
confirm
vivo
assembl
complex
nanovaccin
figur
support
inform
use
immunofluoresc
stain
green
determin
traffick
effici
drain
lymph
node
coloc
follicular
dendrit
cell
blue
contrast
dpi
figur
observ
consist
recent
find
traffick
recombin
protein
nanoparticl
determin
whether
improv
immunogen
traffick
correl
enhanc
adapt
immun
follow
humor
respons
immun
balbc
mice
dpi
found
induc
rapid
seroconvers
figur
decor
ls
nanoparticl
core
essenti
observ
earli
respons
cotransfect
mice
muscl
ratio
ls
core
dlnanolscor
lead
seroconvers
timepoint
figur
support
inform
next
examin
whether
scaffold
simpler
multimer
domain
would
perform
similarli
heptamer
led
limit
seroconvers
dpi
induc
antibodi
titer
lower
figur
support
inform
circul
igm
play
role
protect
measur
induc
igm
respons
found
induc
stronger
igm
respons
two
immun
figur
support
inform
igg
titer
higher
singl
immun
figur
support
inform
two
immun
figur
respect
consist
observ
found
frequenc
b
cell
spleen
mice
immun
higher
rel
mice
immun
figur
even
though
rel
b
cell
recov
per
million
splenocyt
analyz
figur
support
inform
retain
fold
present
key
conform
epitop
vivo
elicit
murin
antibodi
could
outcompet
bind
competit
elisa
figur
support
inform
figur
strike
effect
observ
humor
respons
remark
attenu
dose
figur
support
inform
given
dose
induc
similar
level
antibodi
respons
figur
support
inform
importantli
differ
antibodi
respons
induc
probabl
sole
due
increas
antigen
express
figur
still
outperform
less
monom
dose
figur
abil
improv
humor
respons
observ
anim
model
strikingli
two
immun
mice
fail
induc
seroconvers
induc
strong
humor
respons
figur
support
inform
genet
divers
mice
also
observ
rapid
seroconvers
robust
respons
figur
support
inform
addit
observ
significantli
improv
humor
respons
femal
figur
male
figur
balbc
mice
rel
final
guinea
pig
singl
intraderm
id
vaccin
remark
induc
seroconvers
dpi
higher
antibodi
titer
time
figur
proceed
studi
id
vaccin
guinea
pig
id
deliveri
addit
advantag
simplic
improv
toler
dose
next
compar
antibodi
respons
induc
protein
protein
subcutan
administ
mice
consist
prior
studi
involv
administr
immunogen
mice
rel
high
protein
dose
use
studi
compar
prior
studi
protein
versu
dna
observ
two
sequenti
immun
protein
sigma
adjuv
system
mice
induc
similar
humor
respons
figur
recent
report
uptak
traffick
nanoparticl
depend
mbl
complement
explor
whether
nanoparticl
depend
similar
mechan
similar
previou
humor
respons
elicit
nanoparticl
transgen
mbl
knockout
mice
attenu
compar
wildtyp
mice
dpi
figur
strikingli
similar
humor
respons
induc
mbl
knockout
mice
compar
wildtyp
mice
figur
highlight
dlnano
immunogen
may
act
independ
pathway
potenti
redund
mechan
antigen
present
next
examin
induct
cellular
respons
dna
nanovaccin
elicit
significantli
stronger
antigen
cellular
respons
balbc
mice
determin
assay
figur
intracellular
cytokin
stain
ic
reveal
scaffold
ls
domain
drove
predominantli
respons
sinc
higher
proport
effector
memori
produc
stimul
ls
peptid
peptid
figur
figur
b
support
inform
contrast
found
effector
memori
cell
induc
reactiv
domain
ls
domain
induc
effector
memori
express
activ
cytokin
exhibit
effector
phenotyp
balbc
mice
figur
mice
also
found
elicit
strong
respons
full
immunogen
respons
predomin
ls
domain
possibl
due
lack
epitop
domain
inbr
strain
figur
support
inform
determin
abil
elicit
respons
antigen
domain
model
divers
hla
haplotyp
use
outbr
mice
found
induc
stronger
effector
memori
respons
domain
figur
support
inform
mice
strain
studi
observ
elicit
significantli
higher
frequenc
effector
memori
could
figur
figur
support
inform
addit
observ
induc
stronger
respons
domain
femal
figur
male
figur
support
inform
balbc
mice
comparison
protein
observ
two
immun
higher
respons
assay
figur
addit
ic
reveal
protein
induc
respons
figur
support
inform
nanoparticl
elicit
potent
respons
figur
figur
support
inform
recombin
protein
nanoparticl
fail
induc
respons
wt
transgen
mbl
knockout
mice
wherea
induc
robust
respons
strain
figur
confirm
prior
observ
dlnanovaccin
may
act
independ
pathway
ensur
observ
phenomena
limit
ls
scaffold
nanoparticl
comput
design
addit
nanoparticl
use
crystal
structur
ferritin
helicobact
pylori
mer
pfv
viral
cage
pyrococcu
furiosu
model
variou
geometri
rel
particl
surfac
design
appropri
flexibl
linker
homogen
assembl
spheric
nanoparticl
nsem
figur
support
inform
figur
observ
mix
speci
predomin
peak
ml
retent
time
account
approxim
overal
intens
correspond
nanoparticl
nsem
figur
support
inform
figur
demonstr
decor
design
nanoparticl
recombinantli
produc
protein
test
observ
bind
figur
support
inform
immunofluoresc
demonstr
express
vivo
dpi
figur
even
though
vivo
express
found
stronger
averag
analysi
figur
function
balbc
mice
immun
rapidli
seroconvert
dpi
mount
stronger
antibodi
respons
week
period
mice
immun
figur
addit
balbc
mice
immun
two
dose
develop
stronger
effector
memori
respons
antigen
domain
immun
elispot
ic
assay
figur
figur
e
support
inform
valenc
nanoparticl
found
relev
phenomenon
observ
figur
low
dna
dose
found
nanoparticl
vaccin
heptamer
capabl
induc
seroconvers
balbc
mice
dpi
figur
term
cellular
immun
dose
found
nanovaccin
capabl
induc
improv
immun
rel
figur
overal
observ
aforement
nanoparticl
domain
design
display
antigen
elicit
rapid
strong
adapt
immun
respons
determin
whether
find
could
appli
immunogen
relev
differ
infecti
diseas
comput
design
ls
nanoparticl
display
receptor
bind
domain
head
influenza
hemagglutinin
base
strain
anew
confirm
assembl
homogen
sec
nsem
figur
support
inform
figur
b
phenomenon
observ
remark
low
plasmid
vaccin
dose
induc
significantli
stronger
humor
respons
balbc
mice
figur
hemagglutinin
inhibit
titer
hai
autolog
strain
found
higher
correl
reduct
risk
infect
mice
immun
two
dose
mice
immun
two
dose
figur
final
timepoint
dpi
three
immun
group
develop
bind
hai
antibodi
heterolog
influenza
asolomon
strain
figur
support
inform
figur
bind
hai
titer
still
significantli
higher
group
hai
distant
strain
detect
either
group
addit
term
elicit
cellular
respons
two
immun
induc
higher
effector
memori
respons
dose
term
express
similar
prior
find
figur
figur
support
inform
final
examin
whether
homogen
vitro
assembl
design
dlnanovaccin
prerequisit
enhanc
potenc
end
studi
vivo
properti
poorli
fold
nanoparticl
use
altern
ls
scaffold
influenza
construct
base
strain
pass
biophys
filter
vitro
express
construct
show
peak
two
largest
peak
consist
aggreg
smaller
unassembl
protein
sec
figur
support
inform
found
could
induc
characterist
earli
seroconvers
balbc
mice
figur
support
inform
even
immun
mice
follow
time
antibodi
respons
induc
still
lag
behind
highlight
downstream
success
dlnanovaccin
predic
upon
preliminari
comput
design
biophys
character
evalu
induct
function
immun
respons
dlnanovaccin
util
lethal
influenza
challeng
model
mice
construct
domain
hemagglutinin
strain
leader
sequenc
codon
compar
previous
report
first
confirm
vitro
assembl
nanoparticl
sec
nsem
figur
b
support
inform
immun
three
group
mice
twice
minim
dose
dna
encod
either
control
backbon
pvax
vector
week
apart
observ
improv
induct
bind
antibodi
respons
mice
immun
figur
five
week
first
immun
observ
signific
eightfold
improv
hai
titer
mice
immun
figur
set
two
lethal
influenza
challeng
experi
three
group
mice
week
final
immun
mous
intranas
inocul
homolog
viru
follow
week
weight
loss
mous
lose
baselin
bodi
weight
would
met
human
endpoint
euthanasia
experi
observ
mice
immun
fulli
surviv
lethal
challeng
figur
wherea
mice
immun
mice
immun
control
pvax
backbon
succumb
infect
addit
among
mice
surviv
challeng
substanti
lower
weight
loss
observ
mice
immun
figur
separ
set
experi
follow
three
group
immun
mice
day
post
challeng
determin
lung
viral
load
patholog
observ
challeng
studi
within
first
day
mice
immun
control
pvax
vector
succumb
infect
mice
immun
either
surviv
first
day
figur
even
though
mice
immun
still
lost
substanti
weight
immun
figur
support
inform
addit
observ
signific
reduct
viral
load
mice
immun
compar
mice
immun
pvax
reduct
reduct
figur
final
h
e
stain
lung
specimen
day
challeng
time
euthanasia
reveal
mice
immun
protect
lung
patholog
includ
observ
eosinophil
necrot
deposit
within
alveolar
space
thicken
alveolar
septa
associ
influenza
infect
figur
figur
support
inform
lethal
challeng
studi
illustr
dlnanovaccin
could
confer
signific
function
advantag
infecti
diseas
model
develop
vaccin
challeng
endeavor
due
poor
immunogen
certain
vaccin
antigen
result
need
increas
number
requir
vaccin
dose
per
vaccin
requir
interv
patient
complet
vaccin
regim
particul
vaccin
formul
help
boost
immunogen
slow
develop
larg
scale
due
manufactur
complex
synthet
method
deliveri
vaccin
antigen
shown
great
promis
often
produc
significantli
lower
cost
protein
counterpart
manufactur
scale
bypass
complex
process
offer
superior
safeti
demonstr
remark
thermost
allow
extend
studi
use
comput
model
biophys
character
engin
multimer
form
hiv
influenza
antigen
fold
properli
vitro
display
desir
antigen
profil
show
design
nanovaccin
assembl
vivo
deliv
use
synthet
dna
adapt
ep
direct
evid
page
analysi
figur
transmiss
electron
microscopi
figur
indirect
evid
bind
murin
mbl
vivo
produc
figur
vivo
nanoparticl
assembl
result
improv
antigen
traffick
induct
potent
adapt
immun
respons
includ
rapid
seroconvers
higher
bind
function
hai
antibodi
titer
yet
signific
dose
spare
enhanc
antibodi
respons
also
induc
dlnanovaccin
administ
via
id
dna
vaccin
newer
clinic
import
rout
dna
importantli
enhanc
immun
respons
induc
dlnanovaccin
also
confer
function
advantag
dlnanovaccin
effici
drive
hai
respons
ultim
gener
protect
anim
intranas
influenza
challeng
dna
vaccin
approach
effect
synerg
protein
engin
quickli
produc
vivo
design
nanovaccin
construct
rapid
evalu
work
interrog
factor
might
contribut
enhanc
adapt
immun
respons
dlnanovaccin
homogen
vitro
assembl
comput
design
dlnanovaccin
import
downstream
success
poorli
assembl
elicit
similarli
potent
immun
respons
figur
support
inform
homogen
vitro
assembl
like
help
increas
fraction
fulli
assembl
nanoparticl
vivo
contribut
overal
immunogen
vaccin
theori
possibl
improv
immunogen
describ
attribut
differ
level
antigen
express
howev
two
observ
suggest
antigen
express
sole
respons
improv
respons
first
show
induc
stronger
humor
respons
balbc
mice
less
dose
figur
second
express
higher
level
vivo
figur
induc
similar
antibodi
titer
cell
respons
dose
figur
f
exact
contribut
nanoparticl
assembl
express
valenc
induct
optim
immun
respons
requir
investig
nanovaccin
compar
recombin
protein
nanovaccin
wide
consid
extrem
potent
vaccin
formul
term
induct
antibodi
observ
dlnanovaccin
induc
compar
humor
respons
recombin
protein
nanovaccin
uniqu
induc
potent
respons
manner
observ
dlnanovaccin
function
independ
pathway
like
interest
clinic
translat
vaccin
approxim
human
popul
mbl
defici
plasma
mbl
ng
role
cell
immun
surveil
mediat
protect
provid
strong
rational
explor
uniqu
properti
especi
diseas
influenza
uniqu
abil
dlnano
vaccin
induc
respons
may
relat
distinct
mechan
antigen
uptak
present
cell
macrophag
known
migrat
site
epto
scaveng
antigen
express
dna
cassett
associ
apoptot
prior
studi
observ
dna
vaccin
caspas
fa
significantli
increas
respons
vaccin
distinct
mechan
antigen
process
might
lead
effici
mhc
class
pathway
addit
apc
includ
dc
macrophag
may
also
directli
transfect
inocul
dna
cassett
two
mechan
may
synergist
induct
immun
find
also
demonstr
dlnanovaccin
could
improv
induc
respons
eightfold
tenfold
rel
monomer
counterpart
given
dnavaccin
alreadi
induc
respons
patient
caus
histopatholog
regress
cervic
find
relev
whether
dlnanovaccin
improv
clinic
respons
rate
explor
importantli
signific
dose
spare
realiz
dlnanovaccin
dose
plasmid
dna
dose
histor
would
expect
observ
robust
abl
induc
clear
function
hai
titer
mice
fewer
immun
dlnanovaccin
could
induc
higher
titer
antibodi
given
recent
advanc
ep
technolog
improv
potenc
consist
immun
respons
induc
dna
vaccin
import
determin
whether
dlnanovaccin
also
help
reduc
dose
use
clinic
lower
number
clinic
visit
requir
vaccin
advanc
may
import
implic
outbreak
control
global
deploy
includ
vaccin
resourc
limit
set
import
build
initi
studi
improv
dlnanovaccin
exampl
known
receptor
multival
antigen
display
improv
studi
examin
mechan
improv
respons
dlnanovaccin
rel
monomer
counterpart
also
import
due
uniqu
abil
dlnanovaccin
elicit
strong
immun
new
dlnanovaccin
design
evalu
target
diseas
cancer
depend
infecti
diseas
combin
advantag
simplifi
platform
abil
retain
vivo
structur
integr
may
valu
develop
addit
vaccin
hiv
influenza
well
infecti
diseas
work
demonstr
advanc
synthet
dna
adapt
electropor
technolog
allow
vivo
assembl
complex
comput
design
particul
nanovaccin
induc
improv
humor
cellular
respons
confer
function
protect
benefit
surviv
studi
dna
rapidli
manufactur
scale
low
cost
envis
comput
design
nanovaccin
rapidli
evalu
expedit
clinic
translat
global
deploy
variou
promis
vaccin
candid
author
inform
prior
find
synthet
dna
electropor
use
deliv
vivo
biolog
antibodi
enzym
sought
determin
studi
whether
complex
structur
macromolecular
nanoparticl
assembl
also
deliv
dnaep
nanovaccin
histor
shown
induc
potent
humor
respons
monomer
counterpart
may
challeng
produc
larg
scale
therefor
method
simplifi
process
produc
nanovaccin
host
may
relev
sampl
size
studi
predetermin
power
analys
result
anoth
set
pilot
studi
collect
datapoint
includ
final
analys
except
singl
guinea
pig
group
show
preexist
antibodi
titer
data
collect
least
technic
duplic
except
guinea
pig
challeng
experi
find
replic
success
least
studi
anim
randomli
alloc
cage
initi
studi
random
data
collect
analys
blind
detail
sampl
size
found
figur
legend
statist
test
perform
found
section
statist
nanoparticl
structur
ferritin
pdb
id
ls
pdb
id
pfv
use
seed
model
simul
structur
pdb
id
pdb
id
use
decor
nanoparticl
glycan
miss
densiti
ad
use
glycan
model
modul
new
algorithm
simplenanoparticlemodel
written
molecular
softwar
briefli
appropri
number
immunogen
align
surfac
nanoparticl
use
coordin
frame
construct
atom
termin
posit
protein
immunogen
tilt
random
rotat
around
x
axe
first
simul
last
simul
rotat
allow
z
axi
immunogen
also
translat
along
axi
project
away
nanoparticl
surfac
clash
detect
iter
model
lowest
number
clash
translat
written
potenti
structur
model
model
manual
inspect
util
construct
linker
repeat
use
per
linker
residu
guid
sequenc
ha
isol
anew
residu
use
construct
flu
nanoparticl
protein
sequenc
ige
leader
sequenc
previous
protein
sequenc
pfv
obtain
uniprot
access
number
protein
sequenc
obtain
genbank
access
number
dna
encod
protein
sequenc
codon
rna
optim
previous
optim
transgen
synthes
de
novo
genscript
piscataway
nj
clone
modifi
backbon
control
human
cmv
promot
bovin
growth
hormon
polyadenyl
signal
plasmid
produc
commerci
genscript
aldevron
fargo
nd
low
endotoxin
level
u
cell
transfect
pvax
plasmid
vector
carri
dlnano
transgen
harvest
day
transfect
supernat
first
purifi
affin
chromatographi
use
akta
pure
system
imac
nickel
column
graviti
flow
column
fill
gnl
lectin
bead
dlnano
eluat
fraction
affin
purif
pool
concentr
dialyz
pb
buffer
load
onto
sec
column
purifi
sec
superdex
gl
column
use
purifi
superos
increas
gl
column
use
dlnano
run
ml
identifi
eluat
fraction
collect
concentr
mg
pb
anim
experi
carri
accord
anim
protocol
approv
wistar
institut
institut
anim
care
use
committe
iacuc
philadelphia
pa
immun
week
old
femal
balbc
mice
week
old
male
balbc
mice
purchas
jackson
laboratori
charl
river
laboratori
immun
one
three
time
week
apart
via
intramuscular
inject
tibiali
anterior
muscl
two
site
follow
intramuscular
electropor
cellectra
devic
inovio
pharmaceut
electropor
two
set
two
puls
amp
deliv
set
two
puls
last
ms
delay
immun
except
dose
studi
plasmid
dna
use
standard
dna
dose
prior
control
experi
assess
import
antigen
decor
nanoparticl
balbc
mice
immun
pvax
dlnanol
core
pvax
follow
dpi
seroconvers
immun
dose
use
immun
studi
humor
respons
studi
cellular
respons
mbl
knockout
mice
knockout
mice
nod
purchas
jackson
laboratori
immun
manner
immun
week
old
femal
mbl
knockout
knockout
mice
immun
subcutan
two
site
high
dose
recombin
protein
sigma
adjuv
system
protein
dose
time
higher
prior
femal
hartley
guinea
pig
week
old
purchas
charl
river
laboratori
wilmington
group
hous
handl
acculab
san
diego
ca
ad
libitum
access
food
water
accord
iacuc
protocol
follow
acclim
guinea
pig
given
singl
immun
two
site
flank
follow
id
ep
cellectra
devic
anim
bled
indic
timepoint
humor
analys
corn
half
area
plate
coat
room
temperatur
h
monorab
antibodi
genscript
follow
overnight
block
solut
contain
pb
skim
milk
goat
serum
bsa
fb
plate
incub
room
temperatur
h
follow
addit
mice
sera
serial
dilut
pb
fb
tween
incub
h
plate
incub
room
temperatur
h
peroxidas
affinipur
goat
igg
fragment
specif
dilut
jackson
immunoresearch
affinipur
goat
igm
chain
specif
jackson
immunoresearch
dilut
follow
addit
tmb
substrat
thermo
fisher
scientif
quench
absorb
nm
record
biotek
plate
reader
endpoint
titer
defin
highest
dilut
od
sera
exce
cutoff
mean
od
anim
plu
standard
deviat
od
sera
multipli
standard
deviat
multipli
f
confid
level
plate
coat
block
follow
addit
describ
last
section
serial
dilut
mice
sera
incub
plate
h
follow
addit
purifi
antibodi
nih
aid
reagent
addit
h
room
temperatur
plate
incub
fc
rabbit
mice
jackson
immunoresearch
dilut
h
follow
addit
tmb
substrat
detect
absorb
nm
record
biotek
plate
reader
plate
coat
recombin
mous
mbl
protein
r
system
room
temperatur
h
follow
block
bsa
pb
overnight
transfect
supernat
muscl
homogen
contain
ad
plate
h
incub
follow
week
sera
balbc
mice
previous
immun
twice
plate
incub
igg
hl
human
hrp
jackson
immunoresearch
dilut
follow
addit
tmb
substrat
absorb
nm
record
biotek
plate
reader
elisa
format
describ
section
elisa
except
recombin
mbl
use
coat
step
replac
nih
aid
reagent
absorb
nm
record
biotek
plate
reader
corn
plate
coat
overnight
plate
block
buffer
describ
elisa
section
h
room
temperatur
follow
incub
serial
dilut
room
temperatur
h
plate
incub
fc
rabbit
mice
jackson
immunoresearch
dilut
h
follow
addit
tmb
substrat
detect
absorb
nm
record
biotek
plate
reader
corn
half
area
plate
coat
overnight
recombin
ha
ha
immun
technolog
block
room
temperatur
h
buffer
describ
elisa
section
plate
subsequ
incub
serial
dilut
mous
sera
pb
fb
tween
h
follow
h
incub
igg
hl
hrp
bethyl
dilut
room
temperatur
develop
use
tmb
substrat
absorb
nm
record
biotek
plate
reader
mice
sera
treat
enzym
rde
ratio
overnight
h
follow
complement
enzym
inactiv
min
sera
subsequ
rooster
red
blood
cell
lampir
biolog
pb
h
sera
serial
dilut
pb
microtit
plate
corn
four
hemagglutin
dose
asolomon
viru
anew
bei
ad
well
mixtur
incub
room
temperatur
h
incub
vv
rooster
red
blood
cell
salin
min
room
temperatur
hai
antibodi
titer
score
dot
method
reciproc
highest
dilut
exhibit
agglutin
rooster
red
blood
cell
record
lymph
node
stain
day
balbc
mice
immun
dna
u
hyaluronidas
sigma
encod
tibiali
anterior
muscl
mice
inject
bd
bioscienc
situ
label
follicular
dendrit
cell
h
prior
harvest
ipsilater
iliac
lymph
node
mice
harvest
next
day
preserv
oct
medium
fisher
cryosect
section
fix
paraformaldehyd
block
bsapb
h
room
temperatur
follow
overnight
stain
section
wash
stain
alexa
fluor
antibodi
imag
leica
confoc
microscop
muscl
stain
day
balbc
mice
immun
dna
encod
u
hyaluronidas
tibiali
anterior
muscl
mice
harvest
preserv
pfapb
h
room
temperatur
store
overnight
tissu
serial
dehydr
block
bsapb
h
room
temperatur
follow
overnight
stain
section
wash
stain
alexa
fluor
antibodi
counterstain
dapi
imag
leica
confoc
microscop
transfect
cell
cell
cultur
glass
chamber
overnight
transfect
genejamm
agil
cell
harvest
h
fix
paraformaldehyd
permeabil
triton
block
stain
section
describ
muscl
immunofluoresc
stain
immunohistochemistri
stain
muscl
section
balbc
mice
immun
u
hyaluronidas
sigma
transfect
muscl
harvest
day
cryosect
fix
permeabil
block
describ
immunofluoresc
section
muscl
section
stain
goat
mbl
dilut
bsapb
r
system
overnight
secondari
rabbit
hl
hrp
conjug
dilut
biorad
dab
substrat
develop
tibiali
anterior
muscl
balbc
mice
immun
u
hyaluronidas
collect
dpi
muscl
fix
glutaraldehyd
serial
dehydr
acetoneethanol
solvent
embed
epoxi
lr
white
resin
resin
section
thick
nm
deposit
onto
metal
grid
block
overnight
bsapb
follow
stain
dilut
bsapb
overnight
nm
gold
nanoparticl
jackson
immunoresearch
h
section
wash
tween
pb
water
follow
fixat
glutaraldehyd
pb
min
room
temperatur
follow
stain
uranyl
acet
h
grid
subsequ
imag
jeol
jem
transmiss
electron
microscop
quantit
analys
total
number
cluster
order
cluster
manual
count
frequenc
cluster
particular
order
field
view
normal
rel
total
number
cluster
observ
nanoparticl
produc
cell
purifi
use
lectin
bead
agaros
galanthu
nivali
lectin
vector
laboratori
follow
sec
ge
healthcar
use
superos
increas
gl
column
protein
dialyz
salin
tb
total
purifi
protein
adsorb
onto
glow
discharg
em
grid
grid
stain
uranyl
acet
blot
stain
stain
follow
final
blot
imag
collect
data
process
perform
fei
tecnai
microscop
equip
oneview
gatan
camera
magnif
camera
pixel
size
spleen
immun
mice
collect
week
first
immun
week
second
immun
homogen
suspens
tissu
stomach
rpmi
red
blood
cell
subsequ
lyse
ack
lyse
buffer
thermo
fisher
scientif
percentag
viabl
cell
determin
trypan
blue
exclus
total
cell
plate
well
mous
elispot
plate
mabtech
follow
addit
peptid
pool
span
ls
ha
domain
final
concentr
peptid
genscript
cell
stimul
h
follow
develop
accord
manufactur
instruct
spot
well
imag
count
immunospot
macro
analyz
singl
cell
suspens
spleen
immun
anim
prepar
describ
previou
section
stimul
peptid
span
ls
ha
domain
genscript
h
presenc
protein
transport
inhibitor
thermo
fisher
scientif
thermo
fisher
scientif
cell
incub
violet
fluoresc
reactiv
livedead
dye
min
room
temperatur
surfac
stain
room
temperatur
min
cell
fix
permeabil
accord
manufactur
instruct
bd
cytoperm
cytofix
kit
stain
intracellular
stain
apc
biolegend
h
cell
subsequ
analyz
lsr
ii
flow
cytomet
tibiali
anterior
muscl
immun
anim
harvest
homogen
extract
buffer
thermo
fisher
scientif
proteas
inhibitor
roch
muscl
homogen
subsequ
concentr
amicon
ultra
ml
centrifug
kit
cutoff
milipor
sigma
protein
concentr
quantifi
bca
assay
thermo
fisher
scientif
electrophoresi
supernat
cell
transfect
pvax
muscl
homogen
mice
immun
aforement
construct
u
hyaluronidas
load
onto
sd
gel
gel
page
electrophoresi
sampl
reduc
heat
sampl
presenc
reduc
agent
ld
sampl
buffer
thermo
fisher
scientif
min
page
sampl
incub
ld
buffer
room
temperatur
load
directli
onto
ta
gel
without
boil
protein
subsequ
transfer
pvdf
membran
gel
stain
overnight
gapdh
clone
cell
signal
odyssey
block
tween
bioscienc
irdy
goat
igg
bioscienc
odyssey
block
sd
room
temperatur
h
scan
odyssey
clx
recombin
label
fitc
lightn
link
kit
accord
manufactur
instruct
expedon
spleen
harvest
week
second
immun
mice
singl
cell
label
livedead
dye
ultraviolet
reactiv
thermo
fisher
scientif
room
temperatur
min
incub
mous
clone
thermo
fisher
scientif
dilut
biotinyl
tetramer
excess
thermo
fisher
scientif
previous
cell
wash
pb
incub
min
without
wash
cell
incub
biolegend
thermo
fisher
scientif
biolegend
biolegend
fbspb
solut
cell
resuspend
bdfix
buffer
analyz
lsr
ii
flow
cytomet
six
eight
femal
balbc
mice
jackson
laboratori
immun
pvax
vector
twice
week
apart
mice
subsequ
transfer
bioqual
inc
challeng
experi
day
second
immun
mice
intranas
inocul
pb
weight
mice
prior
challeng
daili
challeng
dpi
lung
mice
harvest
viral
load
assay
histopatholog
h
e
stain
point
mice
exhibit
weight
loss
compar
baselin
euthan
human
endpoint
amount
rna
copi
per
gram
lung
tissu
determin
use
quantit
pcr
qpcr
assay
assay
util
primer
probe
specif
design
amplifi
bind
conserv
region
np
gene
influenza
viru
signal
compar
known
standard
curv
calcul
give
copi
per
gram
tissu
viral
rna
extract
lung
homogen
use
minielut
viru
spin
kit
qiagen
taqman
kit
appli
biosystem
inc
carlsbad
ca
use
amplif
viral
rna
presenc
nm
primer
atggcgtctcaaggcaccaa
gcacatttggatgtagaatctc
nm
probe
follow
thermocycl
set
min
min
follow
cycl
min
power
analysi
perform
r
base
preliminari
data
determin
smallest
sampl
size
would
allow
achiev
power
statist
analys
perform
prism
r
individu
data
point
sampl
independ
rank
test
use
compar
differ
group
bonferroni
correct
use
multipl
comparison
made
zx
dbw
dwk
pend
patent
mcw
pdf
ks
es
keb
lmh
employe
inovio
pharmaceut
receiv
salari
benefit
includ
ownership
stock
stock
option
compani
km
receiv
grant
consult
fee
inovio
relat
dna
vaccin
develop
dbw
receiv
grant
fund
particip
industri
collabor
receiv
speak
honoraria
receiv
fee
consult
includ
serv
scientif
review
committe
board
seri
remuner
receiv
dbw
includ
direct
payment
stock
stock
option
interest
disclosur
note
potenti
conflict
associ
work
inovio
possibl
other
zx
mcw
dbw
dwk
conceptu
project
zx
mcw
stce
pdf
ks
dbw
dwk
plan
experi
zx
mcw
nc
sw
px
xz
rap
pdf
sg
ha
es
conduct
experi
ks
keb
lmh
km
sm
wr
contribut
crucial
reagent
equip
zx
dbw
dwk
analyz
data
zx
dbw
dwk
wrote
articl
